AF
INM icon

Advisornet Financial’s InMed Pharmaceuticals INM Stock Holding History

Advisornet Financial’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$29 – 2134
2024
Q1 		$29 Buy
+4
New +$29 ﹤0.01% 2018

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Advisornet Financial's INM Position: Q2 2024 in Review

Advisornet Financial sold out of InMed Pharmaceuticals (INM) in Q2 2024, closing a stake of 4 shares — an estimated $29 sold.

Advisornet Financial first reported a position in INM in Q1 2024 and held it in 1 quarter. The position peaked at $29 in Q1 2024. 11 funds tracked by Wall St. Rank hold INM as of Q2 2024.

  • Advisornet Financial reported no remaining InMed Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Advisornet Financial sold 4 InMed Pharmaceuticals shares in Q2 2024, an estimated $29.
  • Advisornet Financial first reported a position in InMed Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Advisornet Financial's InMed Pharmaceuticals position peaked at $29 in Q1 2024.
  • 11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2024.

Based on Advisornet Financial's 13F filing for Q2 2024, filed 16 Jul 2024.